TY - JOUR
T1 - LRP10 variants in progressive supranuclear palsy
AU - Vergouw, Leonie J.M.
AU - Melhem, Shamiram
AU - Donker Kaat, Laura
AU - Chiu, Wang Z.
AU - Kuipers, Demy J.S.
AU - Breedveld, Guido
AU - Boon, Agnita J.W.
AU - Wang, Li San
AU - Naj, Adam C.
AU - Mlynarksi, Elizabeth
AU - Cantwell, Laura
AU - Quadri, Marialuisa
AU - Ross, Owen A.
AU - Dickson, Dennis W.
AU - Schellenberg, Gerard D.
AU - van Swieten, John C.
AU - Bonifati, Vincenzo
AU - de Jong, Frank Jan
N1 - Publisher Copyright:
© 2020
PY - 2020/10
Y1 - 2020/10
N2 - The aim of this study was to explore whether variants in LRP10, recently associated with Parkinson's disease and dementia with Lewy bodies, are observed in 2 large cohorts (discovery and validation cohort) of patients with progressive supranuclear palsy (PSP). A total of 950 patients with PSP were enrolled: 246 patients with PSP (n = 85 possible (35%), n = 128 probable (52%), n = 33 definite (13%)) in the discovery cohort and 704 patients with definite PSP in the validation cohort. Sanger sequencing of all LRP10 exons and exon-intron boundaries was performed in the discovery cohort, and whole-exome sequencing was performed in the validation cohort. Two patients from the discovery cohort and 8 patients from the validation cohort carried a rare, heterozygous, and possibly pathogenic LRP10 variant (p.Gly326Asp, p.Asp389Asn, and p.Arg158His, p.Cys220Tyr, p.Thr278Ala, p.Gly306Asp, p.Glu486Asp, p.Arg554∗, p.Arg661Cys). In conclusion, possibly pathogenic LRP10 variants occur in a small fraction of patients with PSP and may be overrepresented in these patients compared with controls. This suggests that possibly pathogenic LRP10 variants may play a role in the development of PSP.
AB - The aim of this study was to explore whether variants in LRP10, recently associated with Parkinson's disease and dementia with Lewy bodies, are observed in 2 large cohorts (discovery and validation cohort) of patients with progressive supranuclear palsy (PSP). A total of 950 patients with PSP were enrolled: 246 patients with PSP (n = 85 possible (35%), n = 128 probable (52%), n = 33 definite (13%)) in the discovery cohort and 704 patients with definite PSP in the validation cohort. Sanger sequencing of all LRP10 exons and exon-intron boundaries was performed in the discovery cohort, and whole-exome sequencing was performed in the validation cohort. Two patients from the discovery cohort and 8 patients from the validation cohort carried a rare, heterozygous, and possibly pathogenic LRP10 variant (p.Gly326Asp, p.Asp389Asn, and p.Arg158His, p.Cys220Tyr, p.Thr278Ala, p.Gly306Asp, p.Glu486Asp, p.Arg554∗, p.Arg661Cys). In conclusion, possibly pathogenic LRP10 variants occur in a small fraction of patients with PSP and may be overrepresented in these patients compared with controls. This suggests that possibly pathogenic LRP10 variants may play a role in the development of PSP.
KW - Genetics
KW - LRP10
KW - Progressive supranuclear palsy
KW - Rare variants
UR - http://www.scopus.com/inward/record.url?scp=85086128224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086128224&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2020.04.016
DO - 10.1016/j.neurobiolaging.2020.04.016
M3 - Article
C2 - 32527607
AN - SCOPUS:85086128224
SN - 0197-4580
VL - 94
SP - 311.e5-311.e10
JO - Neurobiology of aging
JF - Neurobiology of aging
ER -